Oxytocin is an FDA-approved prescription drug substance (marketed as Pitocin and Syntocinon for obstetric indications) and an eligible bulk substance when compounded in accordance with federal standards. This monograph documents analytical and biochemical reference parameters strictly for in vitro and preclinical laboratory research.
Analytical Specifications
Storage Parameters
- Long-term Storage: -20°C or -80°C in sealed vials under inert atmosphere
- Short-term Storage: 2–8°C for up to 1 month (lyophilized form)
- Reconstituted Solution: Store at 4°C (pH 3–5) for ≤7 days or aliquot and freeze at -20°C (avoid repeated freeze-thaw cycles)
- Protection: Shield from light exposure and alkaline conditions (pH >6 accelerates deamidation and disulfide scrambling)
- Oxidation Prevention: Maintain disulfide bond integrity by avoiding reducing agents (DTT, β-mercaptoethanol)
Research Dosing Reference
Note: Dosing information is for research reference only. Oxytocin is intended strictly for laboratory research. USP activity is typically expressed as Units (U) or milliUnits (mU); 1 mg ≈ 500–600 IU.
Mechanism of Action
- Receptor Binding: Selective agonist at the oxytocin receptor (OXTR, Kd ~1–5 nM), a class A G-protein-coupled receptor (GPCR).
- Signal Transduction: Couples primarily to Gq/11 proteins, activating phospholipase C-β (PLC-β), generating IP3 and diacylglycerol (DAG), and mobilizing intracellular Ca2+.
- Peripheral Effects: Stimulates uterine smooth muscle contraction (myometrium) and mammary myoepithelial cell contraction (milk ejection reflex).
- Central Effects: Modulates neural circuits in the amygdala, nucleus accumbens, and hypothalamus involved in social cognition, stress response, and autonomic regulation.
- Half-Life: Plasma half-life of 3–5 minutes (IV) due to rapid enzymatic cleavage by oxytocinase (cystinyl aminopeptidase / LNPEP) in liver, kidney, and placental tissue.
Quality Control Parameters
- Appearance (visual): White to off-white powder; no aggregation
- Disulfide Bridge Confirmation: ESI-MS shows intact cyclic structure; no reduced form detected
- RP-HPLC (purity): Main peak ≥98.0%; no single impurity >0.5%
- Biological Activity (USP): ≥500 IU/mg by rat uterotonic assay
- Enantiomeric Purity: All L-amino acids; no D-isomer contamination
Comparative Neurohypophyseal Peptides
Oxytocin shares high structural homology with arginine vasopressin (AVP), differing at only two positions (Ile3 vs Phe3; Leu8 vs Arg8). This two-residue substitution accounts for the receptor selectivity between OXTR and V1a/V1b/V2 vasopressin receptors.
Primary Scientific References
- du Vigneaud V, Ressler C, Swan JM, Roberts CW, Katsoyannis PG, Gordon S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. J Am Chem Soc. 1953;75(19):4879-4880. DOI: 10.1021/ja01115a553
- Gimpl G, Fahrenholz F. The oxytocin receptor system: structure, function, and regulation. Physiol Rev. 2001;81(2):629-683. DOI: 10.1152/physrev.2001.81.2.629
- National Center for Biotechnology Information. PubChem Compound Summary for Oxytocin. PubChem: Oxytocin